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Background: N-myc (and STAT) interactor (NMI) plays vital roles in tumor growth, progression, and metastasis. In
this study, we identified NMI as a potential tumor suppressor in lung cancer and explored its molecular mechanism
involved in lung cancer progression.
Methods: Human lung cancer cell lines and a mouse xenograft model was used to study the effect of NMI on tumor
growth. The expression of NMI, COX-2 and relevant signaling proteins were examined by Western blot. Tissue microarray
immunohistochemical analysis was performed to assess the correlation between NMI and COX-2 expression in lung
cancer patients.
Results: NMI was highly expressed in normal lung cells and tissues, but lowly expressed in lung cancer cells and tissues.
Overexpression of NMI induced apoptosis, suppressed lung cancer cell growth and migration, which were mediated by
up-regulation of the cleaved caspase-3/9 and down-regulation of phosphorylated PI3K/AKT, MMP2/MMP9, β-cadherin,
and COX-2/PGE2. In contrast, knockdown of NMI promoted lung cancer cell colony formation and migration, which
were correlated with the increased expression of phosphorylated PI3K/AKT, MMP2/MMP9, β-cadherin and COX-2/PGE2.
Further study showed that NMI suppressed COX-2 expression through inhibition of the p50/p65 NF-κB acetylation
mediated by p300. The xenograft lung cancer mouse models also confirmed the NMI-mediated suppression of
tumor growth by inhibiting COX-2 signaling. Moreover, tissue microarray immunohistochemical analysis of lung
adenocarcinomas also demonstrated a negative correlation between NMI and COX-2 expression. Kaplan-Meier
analysis indicated that the patients with high level of NMI had a significantly better prognosis.
Conclusions: Our study showed that NMI suppressed tumor growth by inhibiting PI3K/AKT, MMP2/MMP9, COX-
2/PGE2 signaling pathways and p300-mediated NF-κB acetylation, and predicted a favorable prognosis in human
lung adenocarcinomas, suggesting that NMI was a potential tumor suppressor in lung cancer.
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Lung cancer is becoming the leading cause of cancer-
related deaths worldwide [1, 2]. It is also the most
common incident cancer and the leading cause of
cancer death in China [3]. Non-small-cell lung cancer
(NSCLC) accounts for more than 85% of lung cancer
[4], while adenocarcinoma (AC) accounts for appro-
ximately 60% of all NSCLC and is the most fre-
quently diagnosed subtype of NSCLC [5]. People with
NSCLC can be treated with surgery, chemotherapy,
radiation therapy, targeted therapy, or a combination
of these. Although target therapy against epidermal
growth factor receptor (EGFR) mutations and echino-
derm microtubule-associated protein-like 4-anaplastic
lymphoma kinase (EML4-ALK) rearrangements im-
proved the prognosis in the last decade [6], mutations
in EGFR are only present in 10–26% of NSCLC [7],
and EML4-ALK rearrangements are only found in 4–
5% of NSCLC [8]. Most patients are not associated
with these mutations, and patients with advanced
NSCLC are resistant to chemotherapy and radiother-
apy. Therefore, improvements in lung cancer diagnos-
tics and new treatments are urgently needed.
N-myc (and STAT) interactor (NMI) is a protein
that interacts with NMYC and CMYC (members of
the oncogene Myc family), and other transcription
factors containing a Zip, HLH, or HLH-Zip motif [9].
The NMI protein interacts with all STATs except
STAT2 and augments STAT-mediated transcription in
response to cytokines IL2 and IFN-γ [9]. NMI is an
IFN-γ inducible gene product that interacts with sev-
eral key molecules in carcinogenesis such as SOX10
and TIP60 [10–14]. NMI may augment coactivator
protein recruitment to some specific transcription fac-
tors, enhance the association of p300/CBP coactivator
proteins with STAT1 and STAT5, and together with
p300/CBP, augment IL2 and IFN- γ dependent tran-
scription [9]. Previous studies demonstrated that NMI
expression decreased in the progression of advanced
invasive breast cancers [15–17], and loss of NMI ex-
pression promoted epithelial-mesenchymal-transition
(EMT) [15]. It was also shown that restoring NMI ex-
pression inhibited tumorigenic and metastatic cell
lines from anchorage independent and invasion re-
lated growth, and retarded tumor xenograft growth by
inhibiting the Wnt/β-catenin signaling pathway and
up-regulating Dkk1 [18]. In addition, NMI played a
vital role in autophagy induction. Loss of NMI re-
duced the autophagy responsiveness and chemosensi-
tivity of breast cancer cells [19]. Sun et al. identified
NMI as an interactor of apoptin, a viral apoptosis in-
ducing protein [20]. Nagel et al. discovered that the
interaction between STAT5, NMI and N-myc re-
pressed myocyte enhancing factor 2c and increasedapoptosis in T cell acute lymphoblastic leukemia, sug-
gesting that NMI might be involved in cancer cell
specific apoptosis [21]. However, little is known about
the function of NMI in lung cancer. In this study, we
have found that NMI may promote apoptosis and in-
hibit cell growth and migration in lung cancer cells.
Notably, we have shown that NMI regulates COX-2,
an inducible enzyme that plays a vital role in carcino-
genesis process.
COX-2 plays a key role in multiple pathophy-
siological processes including inflammation and car-
cinogenesis, as it influences apoptosis, angiogenesis,
and invasion [22]. COX-2 is known to produce pros-
taglandin E2 (PGE2) that regulate tumor-associated
angiogenesis, modulate the immune system, promote
cell migration and invasion, and inhibit apoptosis, all
of which promote cancer progression [23]. COX-2 is
overexpressed in a wide range of human cancers,
such as human cancers of colorectal [24, 25], breast
[26], lung [27, 28], bladder [29–31], uterine cervix
[32, 33], liver [34], pancreas [35, 36], prostate [37],
skin [38], esophagus [39, 40] and stomach [41, 42].
COX-2 overexpression is positively related to poor
survival [31, 43, 44], increased metastasis events, and
invasive properties. In addition, COX-2 overexpression
is associated with apoptosis resistance [45], and ab-
normal cell proliferation as a result of apoptotic cell
death inhibition. In contrast, inhibition of COX-2 in-
duces apoptosis signaling in various human cancers
[46–48]. The COX-2 gene promoter contains an NF-
κB response element as well as other cytokine-
dependent (i.e., IL6) response elements [49]. COX-2
expression is transcriptionally controlled by the binding of
activators such as NF-κB and coactivators such as p300 to
the corresponding sites of its promoter [50–53]. However,
it is unclear whether COX-2 expression is regulated by
NMI in human lung cancer cells.
In this study, we investigated the role of NMI in
the regulation of cell proliferation, apoptosis, and mi-
gration in human lung cancers, and also explored its
underlying molecular mechanisms involved in PI3K/
AKT, Erk/p38, MMP9/β-cadherin, NF-κB/COX-2/
PGE2, and PARP/Bcl-2/Caspase3 signaling pathways.
Tissue microarray and immunohistochemical analysis
were also performed to assess the correlation between
NMI and COX-2 expression. Moreover, we further
identified the role of the transcriptional coactivator
p300 in the NMI-mediated regulation of COX-2 ex-
pression and cell growth in lung cancer cells. Finally,
we studied the clinical significance of the NMI/COX-
2 signaling pathways in lung adenocarcinoma patients
using Kaplan-Meier and multivariate survival analyses.
The results from our study not only revealed the
novel role of NMI in regulating lung cancer growth,
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NMI as a new potential tumor suppressor.Methods
Cell lines and cell culture
H1299, HLF (HLF-a) and HBE cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS). A549 and
H460 cells were cultured in RPMI1640 medium supple-
mented with 10% FBS. The cells were grown at 37 °C in
an atmosphere of 5% CO2. All the cell lines were ob-
tained from the American Type Culture Collection
(ATCC, Manassas, VA).Plasmids
The NMI overexpression plasmid pEZ-Lv203-NMI (Cata-
log No.: EX-K2261-Lv203) and its control vector pEX-
NEG-Lv203 (Catalog No.: EX-NEG-Lv203), NMI shRNA
plasmid psi-LVRH1GP-NMI (Catalog No.: HSH022093-
LVRH1GP) and its control vector psi-LVRH1GP (Catalog
No.: CSHCTR001–1-LVRH1GP) were obtained from
GeneCopoeia (Rockville, MD). The target sequence of
NMI shRNA1 is 5′-gagtgcagtcatcacgttt-3′, and the target
sequence of NMI shRNA2 is 5′-ctaggtcaacctcacatag-3′.
A549 and H1299 cells were transfected with correspond-
ing plasmids to overexpress or knock down NMI.Transfection
The cells (2 × 105/ml) seeded in 6-well plates overnight
were mixed gently 4 μg shRNA or plasmids and 10 μl of
Lipofectamine 3000 (Invitrogen, Carlsbad, CA) in 250 μl
opti-MEM (Gibco, Gaithersburg, MD) and incubated at
37 °C for 48 h.Lysate preparation from tumor tissues
Lung cancerous tumors and adjacent tissues were
obtained from 20 lung adenocarcinoma patients who
underwent surgery therapy at the First Affiliated Hos-
pital of Dalian Medical University between 2014 and
2015. The surgery and the study had been approved
by the medical ethics committee at the First Affiliated
Hospital of Dalian Medical University, and the in-
formed consents were obtained from patients in ac-
cordance with the Declaration of Helsinki and with
institutional guidelines. The tissues (100 mg) were
washed with PBS to remove blood, transferred to li-
quid nitrogen immediately and homogenized thor-
oughly with RIPA buffer with protease inhibitor. After
incubation on ice for 30 min, these tissues were soni-
cated for 2 to 5 min at power of about 180 W. The
lysates were centrifuged at 12,000 g for 20 min at 4 °C,
and the supernatants were collected.Western blot
Protein lysates (40 μg) were separated by 4% to 12%
SDS-PAGE, electrophoretically transferred to PVDF
membranes, immunoblotted at 4 °C overnight with anti-
bodies against NMI, p300 (Santa Cruz Biotechnology,
Santa Cruz, CA), β-actin, COX-2, p-PI3K, PI3K p85
(Tyr458)/p55 (Tyr199), Akt, p-Akt (Ser473), p-PDK1, p-
GSK3β, p110 β, P38, p-P38, ERK1/2, pPARP, pTyr202/
Y204-ERK1/2, cleaved caspase-3, cleaved caspase-9,
MMP2, MMP9, E-cadherin, B-cadherin (all purchased
from Cell Signaling Technology, Beverly, MA), Bcl2
(Proteintech, Wuhan, China), followed by incubation
with HRP-conjugated second antibody, and finally de-
tected by enhanced chemiluminescence.
PGE2 assay
Three days after transfection, cell culture media were
collected. The amounts of PGE2 in the media were de-
termined by Human Prostaglandin E2 (PGE2) ELISA Kit
(Bluegene Biotech).
Analysis of promoter activity
The promoter of human COX-2 gene (−891 to +9)
was truncated to 6 different lengths. Each fragment
was inserted into a luciferase reporter vector pGL3.
Luciferase reporter assays were performed using the
kit Dual-Luciferase® Reporter Assay System (Promega,
Madison, WI).
Cell viability assay
Cells were seeded into 96 well plates (4 × 103 cells per
well). Cell viability was measured by MTT assay 48 h
after transfection.
Apoptosis analysis
Cells were transfected with NMI overexpression or
shRNA plasmid. After 48 h, cells were trypsinized,
harvested, washed with PBS twice, and resuspended in
Annexin V Binding Buffer at a concentration of 0.25–
1.0 × 107 cells/ml. 100 μl cell suspension was transferred
to a 5 ml test tube, and 5 μl of APC Annexin V was
added in, followed by the addition of 5 μl 7-AAD Via-
bility Staining solution, per instructions of the Annexin
V APC/7AAD staining kit (Keygen biotech, Jiangsu,
China). Cells were pipetted up and down and incubated
for 15 min at room temperature in the dark. Finally,
400 μl Annexin V Binding Buffer was added to each
tube before the cells were analyze by flow cytometry
(Beckman Coulter, Brea, CA). Apoptosis was measured
in terms of the 7AAD-positive cells.
Scratch assay
Cells were seeded in 6-well plates (4 × 105 cells per
well), and were grouped as (a) PBS control, (b) LacZ
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NMI shRNA1, (f ) NMI shRNA2. 12 h after transfection,
cells were scratched with sterile 200 μl tips, and photo-
graphed at 0 h, 48 h and 72 h.
Confocal immunofluorescence
Cells were incubated on chamber slides in 6-well plates
with or without NMI shRNA transfection. The samples
were fixed with 4% polyoxymethylene for 30 min at room
temperature, permeabilized with PBST (PBS with 0.2%Tri-
ton X-100), blocked with bovine serum albumin (BSA) for
30 min and incubated with NMI and p300 antibodies
(1:200 dilution) overnight at 4 °C. After washed 3 times,
cells were incubated with the fluorescein isothiocyanate
and rhodamine conjugated secondary antibodies for 1 h.
The nuclei were counterstained with 40,6-diamidino-2-
phenylindole (DAPI). The images were taken by Olympus
confocal laser scanning microscope.
Immunoprecipitation (IP)
Nuclear protein (1 mg) was used for each IP. The pro-
teins were pulled down with Protein A/G sepharose and
then detected by Western blot analysis with specific
antibodies.
Animal study
Female nude mice (4 to 5 weeks old) were maintained in
SPF laboratory Animal Central. All animals’ main-
tenance and procedures were carried in accordance with
the National Institute of Health Guide for the Care and
Use of Laboratory Animals, and passed through the
training progress and approval by Animal Care and Eth-
ics Committee of Sun Yat-sen University Cancer Center.
Each nude mouse was injected with 2 × 105 human
A549 cells suspended in 100 μl PBS, subcutaneously
near the axillary fossa. The mice were randomly divided
into 5 groups (6 per group): (a) control plasmid (Ctrl);
(b) NMI overexpression (NMI); (c) control plasmid + li-
popolysaccharides (Ctrl + LPS); (d) NMI overexpression
plasmid + LPS (NMI + LPS); (e) NMI shRNA + LPS
(shRNA + LPS). As a transfection reagent, the complex
of cholesterol-conjugated plasmid (10 μg) suspended in
100 μl saline were injected twice a week for 3 weeks.
The dose of LPS for each mouse is 10 μg/kg, and LPS
was injected twice a week for 2 weeks. Tumors volumes
and body weights were measured every day. Tumor vol-
umes were calculated as V = 1/2 (width2 × length). Mice
were humanely sacrificed by euthanasia after treatment.
Human tissue microarray
The human tissue micro arrays were purchased from
Outdo Biotech Company (Shanghai, China). 75 cases
from 75 lung cancer patients in total were arranged into
two tissue array blocks.Human tissue immunohistochemistry
Slides were deparaffinized, rehydrated and then immersed
in a target retrieval solution (pH 6) and boiled at medium
baking temperature for three times with 10 min once in a
microwave. After blocking the slides with 3% BSA, the
sections were incubated with primary antibodies against
NMI (Santa Cruz Tech., dilution 1:100) and COX-2
(Epitomics, dilution 1:100), and then with HRP-labeled
anti-rabbit IgG secondary antibody. The specimens were
counter stained with hematoxylin. A negative control was
obtained by replacing the primary antibody with a regular
rabbit IgG. The target-positive cells were counted in 3–4
different fields and photographed using an Olympus
microscope, and the immunoreactions were evaluated
independently by two pathologists blinded to the cli-
nicopathologic information to ensure proper tissue
morphology. Antibody staining intensity was categorized:
no staining as 0, weak as 1, moderate as 2, and strong as
3. A five-scale system was used to categorize the percent-
age of cells strained: 0 (no positive cells), 1(<25% positive
cells), 2 (25%–50% positive cells), 3 (50%–75% positive
cells), and 4 (>75% positive cells). The score for each tis-
sue was calculated by multiplying the intensity index with
the percentage scale, and the range of this calculation was
therefore 0–12. The median value of NMI scores was
employed to determine the cutoff. Tumors with NMI
scores lower or equal to the median were designated as
“low expression”, whereas those with scores higher than
the median were designated as “high expression”.
TCGA Data analysis
The mRNA sequencing data of lung adenocarcinoma
samples (n = 576) from The Cancer Genome Atlas
(TCGA) were downloaded from UCSC XENA database,
gene expression RNAseq (IlluminaHiseq pancan nor-
malized) dataset. All samples were divided into three
groups (i.e. high or H, red in heat map; medium or M,
black in heat map; and low or L, green in heat map)
based on raw gene expression values. NMI scores higher
than 66.6% of the patients’ NMI scores were designated
as “high expression”, between 66.6% and 33.3% of the
patients’ were “medium expression”, and lower than
33.3% of the patients’ were “low expression”. All the
samples were selected and used for analysis. The correla-
tions of gene expression were accessed by Pearson cor-
relation coefficient.
Statistical analysis
Student’s t-tests were used to compare two independent
groups of data. Chi-square tests were applied to analyze
the correlation between NMI expression and clinico-
pathologic features of lung adenocarcinomas patients.
Survival curves were constructed using the Kaplan-
Meier method and were compared using the log rank
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used “Enter” modeling to generate models predictive of
outcome. Spearman correlation was used to explore the
relationship between the abundance of NMI and COX-2.
All calculations were performed with IBM SPSS 22 for
Windows (SPSS, New York, NY, USA).
The results were presented as the mean ± SD of three
independent tests. *P < 0.05, **P < 0.01, significant dif-
ference between the treatment and control groups.
Results
The expression of NMI was decreased in lung cancer cells
and tumor tissues
To analyze the expression of NMI in human lung cancer,
we first detected the protein level of NMI in human lung
fibroblasts cell line HLF, immortalized human epithelial
HPV-16 E6/E7 transformed cell line HBE, and human
lung cancer cell lines H322, H1299, H460 and A549 by
Western blot and quantitative analysis. The result
showed that NMI was expressed in all the tested cell
lines, but lung cancer cells (H322, H1299, H460 and
A549) had lower expression of NMI when compared
with HLF cells (Fig. 1a). We next examined the ex-
pression of NMI and COX-2 in tumor tissues and their
adjacent tissues from 20 lung adenocarcinoma patients
using immunohistochemical and quantitative analysis.
We found that 16 out of the 20 tumor samples (T) had
lower expression of NMI and higher expression of COX-
2 compared to their adjacent normal tissue samples (N).
Five representative tumor (T)/normal (N) pairs were
shown in Fig. 1b. This result was consistent with the ob-
servation in lung cancer cell lines H460 and A549 com-
pared to normal cell line HLF (Fig. 1a). These data
indicated that the expression of NMI may be negatively
correlated with COX-2 levels in lung adenocarcinoma
cases. We further investigated the expression of NMI in
lung cancer tissues by immunohistochemistry assay. 75
tumor tissues and their adjacent normal tissues were
tested, and NMI expression was observed in the nucleus
and the cytoplasm of the cells in both tumor tissues and
normal tissues. Among the 75 tumor tissues, 15 showed
strong NMI expression, 33 moderate, 22 weak, and 5
negative. In contrast, among the 75 adjacent normal tis-
sues, 29 showed strong expression of NMI protein, 35
moderate, 8 weak, and 3 negative (Fig. 1c). The repre-
sentative images for NMI expression in lung cancer tis-
sues and normal tissues were shown in Fig. 1d. These
results suggested that NMI had lower expression in lung
cancer cells and tissues.
NMI inhibited proliferation and induced apoptosis of lung
cancer cells
The effect of NMI on lung adenocarcinoma cell prolifer-
ation was evaluated in lung cancer cell lines A549 andH460 by colony formation and quantitative analyses.
NMI overexpression significantly inhibited the prolifera-
tion of both A549 and H460 cells. In contrast, knock-
down of NMI remarkably promoted the proliferation
and increased the clone volume of A549 and H460 cells
(Fig. 2a). These results indicated that NMI played an im-
portant role in regulating lung adenocarcinoma cell pro-
liferation. Next, the effect of NMI on apoptosis was
investigated by Annexin V APC-7AAD staining-based
FACS analysis. Overexpression of NMI significantly in-
duced apoptosis in both A549 and H460 cells (Fig. 2b).
We then examined the effect of NMI on the expression
and activation of four key proteins in the apoptosis sig-
naling pathway: Bcl-2, caspase-3, caspase-9, and PARP
in A549 and H460 cells. Overexpression of NMI re-
pressed the anti-apoptotic protein Bcl-2, and activated
caspase-3, caspase-9 and PARP, which was indicated by
marked increases in cleaved caspase-3, cleaved caspase-9
and phosphorylated PARP (Fig. 2c). Thus, these results
indicated that NMI might control several aspects of
apoptosis signaling. To further identify the potential mo-
lecular mechanisms by which NMI inhibited lung cancer
cell growth, we analyzed the expression of a series of
pro-survival proteins possibly affected by NMI by West-
ern blot and quantitative analysis. The results showed
that NMI knockdown in A549 and H460 cells drama-
tically enhanced the phosphorylation of PI3K, AKT,
PDK1, GSK-3β and p110 β proteins, but did not change
the expression of total PI3K, AKT proteins themselves
(Fig. 2d). On the contrary, overexpression of NMI in
A549 and H460 cells significantly inhibited the phos-
phorylation of PI3K, AKT, PDK1, GSK-3β, and p110 β
proteins, without changing the levels of total PI3K and
AKT (Fig. 2e). We also observed the up-regulation of
the phosphorylation of ERK and p38 in the MAPK sig-
naling pathway upon NMI silencing (Fig. 2d). These data
suggested the possible involvement of PI3K/AKT/MAPK
signaling pathways in NMI-mediated lung cancer cell
growth inhibition.
NMI inhibited lung cancer cell migration
We further investigated whether the NMI-mediated in-
hibition in lung cancer cells was associated with the
impeded cell migration ability. We examined the effect
of NMI overexpression or knockdown on the migration
of A549 and H460 cells by scratch assay. The gap be-
tween cell layers made by a scratch was much wider in
the NMI-overexpressed cells, but it was much narrower
in the NMI-knockdown cells (Fig. 3a, b). Additionally,
the expression of MMP2 and MMP9, two key molecules
involved in cell migration, was significantly increased in
NMI-knockdown cells. Meanwhile, the expression of E-
cadherin, which plays a critical role in cell adhesion, was
markedly down-regulated, whereas the expression of
ab
c d
Fig. 1 The expression of NMI was down-regulated in lung cancer cells and tumor tissues. a Western blot and quantitative analysis of NMI protein
expression in human normal lung fibroblasts cells (HLF), immortalized human epidermal cells (HBE) and lung cancer cells (H322, H1299, H460 and
A549). b Western blot and quantitative analysis of the expression of NMI protein in human lung cancer tissues (T) and adjacent normal lung tissues (N).
c The distribution of lung adenocarcinoma patients with various levels of NMI expression in tumor tissues and adjacent normal lung tissues (n = 75).
d Representative images of NMI immunohistochemical (IHC) staining in human lung adenocarcinoma tissues and adjacent normal lung tissues
(10× magnification)
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the NMI-overexpressed cells, MMP9 and β-cadherin
was down-regulated, whereas E-cadherin was up-
regulated (Fig. 3d). These results indicated that NMI
played a vital role in the inhibition of cancer cell
migration.
NMI inhibited transcriptional activation of COX-2 and
PGE2 production
As NMI expression was inversely correlated with COX-
2 expression in lung adenocarcinoma (Fig. 1a, b), wetested if NMI regulated COX-2 transcription through
interacting with its promoter in lung adenocarcinoma
cells. We inserted the full-length promoter of COX-2
(−891 to +9) as well as the truncated promoters COX-2
(−459 to +9), COX-2 (−362 to +9), COX-2 (−193 to
+9), COX-2 (−96 to +9) and COX-2 (−53 to +9) into
the luciferase reporter vector (Fig. 4a). Luciferase activ-
ity assay showed that overexpression of NMI in A549
cells significantly repressed promoters COX-2 (−891 to
+9) and COX-2 (−459 to +9) (Fig. 4b). We further con-
firmed that overexpression of NMI in A549 and H460
ab c
e
d
Fig. 2 (See legend on next page.)
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Fig. 2 NMI inhibited clone formation and induced apoptosis in lung cancer cells. a Colony formation assay and quantitative analysis were performed
with in A549 and H460 cells with NMI overexpression or knockdown. b FACS analysis was used to determine the relative percentage of
apoptotic cells in A549 and H460 cells. c Western blot and quantitative analysis were used to detected the expression of Bcl-2, cleaved
caspase-3/9 and phosphorylated PARP proteins in A549 and H460 cells at 48 h after transfection with NMI or control plasmids. d Western blot
and quantitative analysis were used to detected the levels of phosphorylated PI3K, AKT, ERK, PKDK1, GSK-3β, p110β and p38 proteins in A549
and H460 cells at 48 h after transfection with NMI-shRNAs or control. e Western blot and quantitative analysis were used to detected the
expression of the phosphorylated PI3K, AKT, pDK1, GSK-3β and p110β proteins in A549 and H460 cells at 48 h after transfection with NMI
overexpression or control plasmids
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while knockdown of NMI increased COX-2 expression
in both A549 and H460 cells (Fig. 4d). In addition,
overexpression of NMI in A549 and H1299 cells signifi-
cantly reduced PGE2 production (Fig. 4e), which wasa
b
c
Fig. 3 NMI inhibited lung cancer cell migration. a Scratch assay was used t
transfection with NMI overexpression/control plasmids or NMI shRNAs/con
quantitative analysis were used to detected the expression of MMP2, MMPconsistent with inhibited COX-2 expression. Cell viabil-
ity assay showed that overexpression of NMI caused
significant cell death in A549 and H1299 cells (Fig. 4f ),
which might be a result of apoptosis induced by COX-2
inhibition [46–48].d
o detected the cell migration in A549 and H460 cells at 72 h after
trol plasmids. b Quantification of scratch assay. c, d Western blot and
9, E-cadherin and B-cadherin in A549 and H460 cells
a c
b d
e
f
Fig. 4 NMI regulated transcriptional activation of COX-2 and PGE2 production. a Schematic diagram of 6 different fragments of COX-2 promoter.
b The activity of different fragments of COX-2 promoter was determined by luciferase reporter assay performed in A549 cells transfected with the
control LacZ plasmid or the NMI overexpression plasmid. c, d Western blot and quantitative analysis were used to detected the expression of
COX-2 in A549 and H460 cells with NMI overexpression (C) or NMI knockdown (D). e The PGE2 production level was measured in A549 and H1299 cell
culture media at 72 h after transfection. f Cell viability was determined by MTT assay in A549 and H1299 cells
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p300 is an important transcripional co-activator for
COX-2 transcription and has been shown to acetylate
COX-2 promoter-bound transactivators such as NF-κB
to activate COX-2 expression [50]. To determine
whether p300 plays a role in the NMI-mediated regu-
lation of COX-2 transcription, we first examined the
interaction between p300 and NMI. We queried the
NCI-Cancer Genome Atlas (TCGA) data base for lung
adenocarcinoma samples (n = 576), and found that the
expression of NMI and p300 were inversely correlated,with Pearson correlation coefficient of −0.322 and
P < 0.05 (Fig. 5a, b). Immunofluorescence assay showed
that the expression of p300 increased when NMI was
knocked down (Fig. 5c). Next, we analyzed the subcellu-
lar localization of p300 and NMI in A549 and H1299
cells by immunofluorescence staining, and found that
NMI and p300 co-localized in the cells (Fig. 5d). Fur-
thermore, we observed in A549 cells that nuclear p300
was decreased when NMI was overexpressed, but was
increased when NMI was knocked down (Fig. 5e, upper
panel). Consistently, the acetylation level of p50 and p65
ab
ec
d
Fig. 5 NMI regulated COX-2 transcription through p300. a TCGA data was analyzed for the correlation of NMI and p300 gene expression levels
(n = 576). Red = high, black = medium, green = low. b Negative correlation in the expression of NMI and p300 was determined in TCGA database.
c The expression of p300 in A549 cells with NMI knockdown was detected by immunofluorescence. d The subcellular localization of NMI and
p300 in H1299 and A549 cells were examined by confocal microscopy. More than 100 cells were inspected per experiment, and cells with typical
morphology were presented. e The expression of the nuclear p300 (upper panel), and the level of the nuclear p50 and p65 pulled down by the
anti-pan-acetyl antibody (i.e. acetylated p50 and p65 in the nucleus, lower panel) were detected by western blot 48 h after transfection
Wang et al. Molecular Cancer  (2017) 16:158 Page 10 of 17NF-κB, the nuclear targets of p300, was decreased in the
NMI-overexpressed cells, but increased in the NMI-
knockdown cells (Fig. 5e, lower panel). These results in-
dicated that NMI might repress COX-2 expression by
inhibiting p300. To confirm these results, we ove-
rexpressed p300 together with NMI in lung cancer cell
line A549. The results showed that overexpression ofp300, but not its histone acetyl transferase (HAT) do-
main deletion mutant (DHAT), was able to rescue the
decreases in cell viability caused by NMI overexpression
(Fig. 6a). Consistently, p300 transfection in the NMI-
overexpressed A549 cells also rescued the transcriptional
inhibition of COX-2 promoter (Fig. 6b) and PGE2
production (Fig. 6c).
a b
c
Fig. 6 Overexpression of p300 reversed the cellular effects caused by NMI overexpression. a Cell viability was measured by MTT assay in A549
cells transfected with LacZ control plasmid, NMI overexpression plasmid, NMI + p300 overexpression plasmids, or NMI + HAT domain-deleted
p300 overexpression plasmids. b COX-2 promoter activity was determined by luciferase reporter assay in A549 cells transfected with NMI and
p300 overexpression plasmids. c PGE2 level was detected in the culture media of A549 cells transfected with NMI and p300 overexpression
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xenograft mouse model
We validated the the suppression of NMI on lung cancer
cell growth via the COX-2 in a xenograft mouse model.
The A549 cells stably expressing NMI were injected into
nude mice (flank) to establish human tumor xenograft.
The results showed that overexpression of NMI signifi-
cantly reduced tumor volume (Fig. 7a–e) and tumor
weight (Fig. 7d). Lipopolysaccharide (LPS) is a COX-2
inducer and has been shown to be able to promote
tumor growth. We found that LPS treatment could over-
come the tumor growth inhibition caused by NMI over-
expression (Fig. 7a-e). More importantly, knockdown of
NMI combined with LPS treatment increased both the
volume and weight of tumors, compared with the con-
trol group treated with LPS treatment alone (Fig. 7a-e).
Moreover, immunohistochemical staining showed that
NMI expression was negatively correlated with COX-2
expression in xenograft tumor tissues (Fig. 7f ). These
data further supported that NMI inhibited tumor cell
growth through the suppression of COX-2 signaling in
lung adenocarcinoma cells.High NMI expression was correlated with low COX-2 ex-
pression and predicted favorable prognosis in NSCLC
patients
We next evaluated the expression of NMI and COX-2 in
tumor samples from 75 NSCLC patients by immunohis-
tochemical (IHC) staining of tissue microarray. The ex-
pression of NMI and COX-2 in each IHC sample was
classified either as high (score > 6) or low (score ≤ 6),
using the median of the IHC scores as the cut-off value.
We found that the expression of COX-2 was negatively
correlated with NMI expression (Fig. 8a, b) (Pearson
correlation coefficient − 0.427, P < 0.001).
Kaplan-Meier analyses of the overall survival revealed
that the high NMI expression group (IHC staining with
strong and moderate expression) had a better prognosis
than the low NMI group (IHC staining with weak and
negative expression) (P < 0.01) (Fig. 8c). In addition, we
further assessed the correlation between NMI expression
and lung adenocarcinoma patients’ overall survival in a
720 lung adenocarcinoma patient cohort from the
KMPLOT database (http://www.kmplot.com) by Kaplan-
Meier analyses, and found that NMI high expression
ba
c
f
d e
Fig. 7 Overexpression of NMI suppressed tumor growth in a xenograft mouse model. Human A549 cells transfected respectively with (1) control
plasmid (Ctrl), (2) NMI overexpression plasmid (NMI), (3) Ctrl + LPS, (4) NMI + LPS, (5) NMI shRNA + LPS (shRNA + LPS) were injected into the right
flank of nude mice (n = 6 per group). a Tumors from the mice after sacrifice. b Representative images of the xenograft-bearing mice. c Tumor volume
of each mouse at the time of sacrifice was measured. d Tumor weight of each mouse at the end of the experiment was measured. e Tumor volume
of each mouse was recorded every three days during the course of the experiment. f The expression of NMI and COX-2 in xenografts were detected
by HE and immunohistochemical staining (400 × magnification)
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than NMI low expression patients in the 720 lung
adenocarcinoma patient (Fig. 8d).
For the 75 lung adenocarcinoma patients in our study,
the correlation between NMI expression and clinico-
pathologic features was further evaluated and summa-
rized in Table 1. The data showed no significant
correlation between NMI downregulation and patient’s
gender (P = 0.351, χ2 tests), age (≥60 vs. <60 years old)
(P = 0.816, χ2 tests), T classification (P = 0.443, χ2 tests)
and N classification (P = 0.451, χ2 tests). We next used aunivariate analysis to evaluate associations between pa-
tient prognosis and several clinicopathologic factors in-
cluding NMI expression (high vs. low), gender (male vs.
female), age (≥60 vs. <60 years old), T stage (T3-T4
vs.T1) and N stage (N2 + N3 + Nx vs. N0 + N1). The re-
sults showed that high NMI expression was significantly
associated with inferior overall survival (P = 0.008,
HR = 0.378) (Table 2). Multivariate analysis also indi-
cated that high NMI level was an independent prognos-
tic factor for overall survival in patients with lung
adenocarcinomas (Table 2). Taken together, all these
ab
c d
Fig. 8 (See legend on next page.)
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Fig. 8 High NMI expression was correlated with low COX-2 expression and predicted favorable prognosis in NSCLC patients. a Representative
images of the immunohistochemical staining of NMI and COX-2 in human lung adenocarcinoma tissues. b NMI expression was negatively
correlated with COX-2 expression in lung adenocarcinoma samples (Pearson’s correlation test, R = −0.427, P < 0.001). c Kaplan-Meier analysis of
the overall survival of 75 lung adenocarcinoma patients with different NMI expression. d Kaplan-Meier analysis of the overall survival of 720 lung
adenocarcinoma patients with different NMI expression in KM PLOTTER database
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cated better prognosis of lung adenocarcinoma patients.Discussion
The data presented here have demonstrated that NMI
functions as a COX-2 regulator in human NSCLC cells.
Up-regulated expression of COX-2 in various cancers
[37] and loss of NMI expression in advanced breast can-
cer [15] have been documented independently. Our data
suggest that NMI plays a crucial role in the regulation of
COX-2 transactivation. Overexpression of NMI resulted
in the decrease of COX-2 expression and PGE2 produc-
tion. Conversely, knockdown of NMI promoted COX-2
expression and PGE2 production. Overexpression of
NMI in lung adenocarcinoma cells also inhibited cell
proliferation and migration. In addition, we found that
NMI expression was lower in lung cancer tumor tissues
compared to the adjacent normal tissues. More import-
antly, human tissue arrays revealed that overexpression
of NMI indicated a better prognosis in lung adenocar-
cinoma patients. Consistent with our results, recent re-
ports have also shown that NMI inhibited tumor
development [18]. Devine et al. found that NMI protein
expression is higher in early stage breast cancer than in
later stages, with the lowest expression observed in pa-
tients with stage IV breast cancer. Moreover, NMI
mRNA expression is inversely related to the grade ofTable 1 Association of NMI expression with patients’ clinicopatholo
Total adenocarcinoma (N = 75) NMI low e
Gender
Male 39 20 (51.3%
Female 36 23 (63.9%
Age at diagnosis
< 60 43 24 (55.8%
≥ 60 32 19 (59.4%
pT factor
T1 21 9 (42.9%)
T2 42 25 (59.5%
T3 + T4 12 6 (50%)
pN factor
N0 + N1 52 28 (53.8%
N2 + N3 + NX 23 15 (65.2%clinical breast cancer specimens, indicating that the loss
of NMI correlates with progression to aggressive disease
[15]. Thus, loss of NMI may be associated with the pro-
gression of cancer.
In our study, we found that there was a significant nega-
tive correlation (Pearson correlation coefficient − 0.322,
P = 0.011) between the expression of NMI and p300 in
lung adenocarcinoma in TCGA database which contains
576 samples. In our own cohort containing 75 paired
NSCLC normal and tumor samples, we also revealed a
negative correlation between the expression of NMI and
COX-2. More importantly, down-regulation of NMI was
associated with poor survival of patients, which is further
validated using the public database containing 720
patients. These data suggest NMI may function as a tumor
suppressor in NSCLC. However, in this study, we used
only a small volume of samples (75 totally). For the T
stage, most of the patients (42 patients) were T2. Thus, we
compared the survival between T3/T4 versus T1 groups.
We could see a trend towards poorer survival for the late
T stage group (the left figure). For the N stage, N0 and N1
samples were merged (52 totally) and compared to the
rest of samples (23 totally). We could see a similar trend
towards poorer survival in the late N stage group (the
right figure). Unfortunately, the difference in both com-
parisons were in-significant. This may be caused by the
small sample volumes, in the future study, we will increase
sample sizes to solve the problem.gical features in human lung adenocarcinoma (n = 75)
xpression (N = 43) NMI high expression (N = 43) p
) 19 (48.7%) 0.351
) 13 (36.1%)
) 19 (44.2%) 0.816
) 13 (40.6)
12 (57.1%) 0.443
) 17 (40.5%)
6 (50%)
) 24 (46.2%) 0.4513
) 8 (34.8%)
Table 2 Cox proportional hazards model analysis of various prognostic factors in patients with lung adenocarcinoma
Hazard ratio 95% Confidence interval Unfavorable/Favorable p
Univariate analysis
NMI 0.378 (0.176, 0.813) Low/High 0.008
Gender 1.069 (0.545, 2.097) Male/Female 0.847
Age, y 0.795392 (0.398, 1.589) <60y/≥60y 0.517
pT factor 1.382 (0.835, 2.289) T3 + T4/T1 0.209
pN factor 1.39 (0.687, 2.813) N2 + N3 + NX/N0 + N1 0.359
Multivariate analysis
NMI 0.370 (0.171, 0.800) Low/High 0.011
pT factor 1.441 (0.840, 2.474) T3 + T4/T1 0.185
pN factor 1.391 (0.577, 2.457) N2 + N3 + NX/N0 + N1 0.637
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and low expression groups crossed at 170 months in a
720 lung adenocarcinoma patient cohort from the
KMPLOT database This mabe be due to several outlier
patients who live for quite long time, which is not usu-
ally seen for lung cancer. A plausible explanation may be
that those patients are actually died of other causes. As a
result, the two curves tend to overlap after long time fol-
lowup. If looking at the earlier parts of the curves, such
as five years or ten years, the two groups are actually
widely separated.
In our current study, we didn’t observe a perfect in-
verse correlation between NMI and COX-2 in our ran-
domly selected 4 cell lines. Two cell lines H322 and
H1299 showed low NMI expression but negative COX-2
expression. This may reflect the complex regulatory net-
work of COX-2 in cancer cells. Actually, many other fac-
tors, such as IL-1 and HIF1α, have been identified to
regulate COX-2 expression. It’s possible that these un-
known factors may interfere with NMI/COX-2 signaling.
However, in a much larger cohort of clinical samples, we
observed a statistically significant inverse correlation be-
tween NMI and COX-2.
As a common transcriptional coactivator, p300 has
been proved to be involved in the regulation of COX-2
gene expression. We therefore hypothesized that p300
interact with NMI, and they have opposite effect on the
regulation of COX-2 expression. Our data supported the
hypothesis that overexpression of NMI reduced nuclear
p300 localization and the acetylation of its targets p50
and p65 NF-kB. Moreover, the elevated p300 level could
rescue the inhibition of COX-2 expression and cell pro-
liferation in NMI overexpressed cells. These data indi-
cate p300 may play an important role in the NMI-
mediated regulation of COX-2 expression in lung adeno-
carcinoma cells. Further studies are needed to confirm
the detailed molecular mechanisms by which NMI regu-
lates COX-2 expression.Conclusions
In summary, we have discovered that NMI plays an im-
portant role in the regulation of COX-2 expression and
tumor growth in lung adenocarcinoma, and high expres-
sion of NMI suggests to a better prognosis in human
adenocarcinoma. Our study therefore suggests that the
NMI/COX-2 signaling pathway is a potential prognostic
biomarker for lung cancers.
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